This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
We have developed autologous bone marrow cell infusion (ABMi) therapy, which was a method of liver regeneration for liver
cirrhotic patients using non-cultured autologous whole bone marrow cells, and reported the efficacy and safety of this approach.
We recently also confirmed that frequent BMC infusion contributed to suppressed tumor initiation during stages of hepatocarcinogenesis
through the stabilization of redox homeostasis in hepatocarcinogenic mice with liver cirrhosis. On the other hand, our ABMi therapy
involves bone marrow aspiration under general anesthesia, and is not indicated for patients for whom general anesthesia is difficult. We
therefore aimed to develop a less-invasive liver regeneration therapy in which cells having curative effect(s) on liver cirrhosis are isolated
and cultured from a small amount of autologous bone marrow aspirated under local anesthesia and infused back into the same patient,
showing that the indications would be able to be expanded, as collection of bone marrow fluid would no longer need to be performed
under general anesthesia. We revealed that the infusion of cultured human bone marrow derived CD73/CD90/CD105 positive and
CD45 negative cells with fetal bovine serum (FBS)-containing D-MEM medium, which were having mesenchymal characteristics,
reduced hepatic fibrosis in the immunodeficient NOD-SCID cirrhotic mice, consistent with the reduced oxidative stress in human
stellate cells co-cultured with human mesenchymal stem cells
. For the clinical trial using cultured bone marrow mesenchymal
stem cells, we are now preparing safety evaluation guidelines and a system conforming to Standard Operating Procedure (SOP) at a
Good Manufacturing Practice (GMP)-grade cell-processing center in our university hospital. Here, we present the current status and
prospects for our liver regeneration therapy using autologous bone marrow-derived cells.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals